Scott M Dehm

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors
    Scott M Dehm
    Department of Biochemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E5, Canada
    Mol Cell Biol 24:2296-307. 2004
  2. ncbi SRC gene expression in human cancer: the role of transcriptional activation
    Scott M Dehm
    Department of Biochemistry, University of Saskatchewan, Saskatoon, Canada
    Biochem Cell Biol 82:263-74. 2004
  3. ncbi Regulation of alternative SRC promoter usage in HepG2 hepatocellular carcinoma cells
    Scott M Dehm
    Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, Canada
    Gene 337:141-50. 2004
  4. ncbi Regulation of androgen receptor signaling in prostate cancer
    Scott M Dehm
    Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 5:63-74. 2005
  5. pmc Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
    Scott M Dehm
    Department of Urology and Biochemistry, Mayo Clinical College of Medicine, Rochester, Minnesota, USA
    Cancer Res 68:5469-77. 2008
  6. ncbi Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells
    Scott M Dehm
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 281:27882-93. 2006
  7. pmc Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis
    Kristin A Raclaw
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Prostate 68:1696-706. 2008
  8. ncbi Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells
    Scott M Dehm
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 67:10067-77. 2007
  9. ncbi Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer
    Hannelore V Heemers
    Department of Urology Research Biochemistry, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Res 67:10592-9. 2007
  10. ncbi p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6
    Jose D Debes
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 65:5965-73. 2005

Collaborators

Detail Information

Publications14

  1. pmc SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors
    Scott M Dehm
    Department of Biochemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E5, Canada
    Mol Cell Biol 24:2296-307. 2004
    ....
  2. ncbi SRC gene expression in human cancer: the role of transcriptional activation
    Scott M Dehm
    Department of Biochemistry, University of Saskatchewan, Saskatoon, Canada
    Biochem Cell Biol 82:263-74. 2004
    ..Analysis of the mechanisms behind HDAC inhibitor mediated repression could be utilized in the future to specifically inhibit SRC gene expression in human cancer...
  3. ncbi Regulation of alternative SRC promoter usage in HepG2 hepatocellular carcinoma cells
    Scott M Dehm
    Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, Canada
    Gene 337:141-50. 2004
    ..This approach identified a HepG2-specific DH site that displayed activating potential towards the SRC1alpha promoter. These results thus provide important insight to the mechanism of SRC transcriptional activation in liver cancer cells...
  4. ncbi Regulation of androgen receptor signaling in prostate cancer
    Scott M Dehm
    Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 5:63-74. 2005
    ..How these mechanisms of androgen receptor activation could be targeted in this advanced stage of the disease is also discussed...
  5. pmc Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
    Scott M Dehm
    Department of Urology and Biochemistry, Mayo Clinical College of Medicine, Rochester, Minnesota, USA
    Cancer Res 68:5469-77. 2008
    ..Together, our data describe a simple and effective mechanism by which PCa cells can synthesize a constitutively active AR and thus circumvent androgen ablation...
  6. ncbi Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells
    Scott M Dehm
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 281:27882-93. 2006
    ..Our data thus demonstrate that the AR can inappropriately activate transcription in ADI PCa cells via mechanisms that are resistant to castration and AR antagonism, the two modes of androgen ablation used to treat advanced PCa...
  7. pmc Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis
    Kristin A Raclaw
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Prostate 68:1696-706. 2008
    ..In the current study, we examined the androgenic regulation of FLIP and its contribution to protecting prostate cancer cells from death receptor-mediated apoptosis...
  8. ncbi Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells
    Scott M Dehm
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 67:10067-77. 2007
    ..These data show that ligand-dependent and ligand-independent AR activation rely on fundamentally distinct mechanisms, and define WxxLF as the major transactivation motif within the AR TAU5 domain...
  9. ncbi Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer
    Hannelore V Heemers
    Department of Urology Research Biochemistry, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Res 67:10592-9. 2007
    ..These results suggest a novel indirect mechanism of androgen action on FHL2 expression and provide evidence that SRF is an important determinant of AR action in prostate cancer cells...
  10. ncbi p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6
    Jose D Debes
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 65:5965-73. 2005
    ....
  11. ncbi Androgen receptor structural and functional elements: role and regulation in prostate cancer
    Scott M Dehm
    Departments of Urology and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, Minnesota 55905, USA
    Mol Endocrinol 21:2855-63. 2007
    ..A comprehensive understanding of the role and functional relationships between these AR domains could lead to the development of novel AR-directed therapies for prostate cancer...
  12. ncbi Molecular regulation of androgen action in prostate cancer
    Scott M Dehm
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Cell Biochem 99:333-44. 2006
    ..We will also summarize several recent studies that have attempted to unravel how these genes are deregulated in androgen depletion independent prostate cancer...
  13. ncbi The modification of Sp3 isoforms by SUMOylation has differential effects on the SRC1A promoter
    Danielle J P Ellis
    Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, SK, Canada
    Gene 379:68-78. 2006
    ..These results provide new insights into the complexity of Sp3 mediated transcription which appears to be highly dependent on the isoform bound, SUMOylation status and the promoter context...
  14. ncbi The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases
    Calley L Kostyniuk
    Department of Biochemistry, University of Saskatchewan, Saskatoon SK, Canada S7N 5E5
    Oncogene 21:6340-7. 2002
    ..Our finding that sodium butyrate and Trichostatin A inhibit both SRC promoters suggest this oncogene may be a major target of these agents, and may explain in part their anti-cancer activity...